Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06746116 | A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain | PHASE3 | ACTIVE NOT_RECRUITING | 45 | — | — | Dec 30, 2024 | Nov 30, 2028 | Apr 16, 2026 | 24 | Spain |
Safety and tolerability will be evaluated in terms of Adverse Events (AEs), Serious AEs (SAEs), and immune-mediated AEs (imAEs)
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | Durvalumab + Chemotherapy (chemotherapy phase) plus Durvalumab + Olaparib (maintenence phase) |
| Name | Type | Description |
|---|---|---|
| Durvalumab + Chemotherapy phase | DRUG | Durvalumab (IV) with SoC (carboplatin + paclitaxel chemotherapy: patients should receive at least 4, but preferably 6 cycles) every three weeks. |
| Durvalumab + Olaparib phase | DRUG | durvalumab (IV) with olaparib (tablets) every four weeks until progression. |
INCLUSION CRITERIA Disease characteristics 3. Histologically confirmed diagnosis of endometrial carcinoma (all histologies, including carcinosarcoma) with archival or recent biopsy available to send at study entry. 4\. Only patients with pMMR tumors are allowed (mismatch repair status determined l...